- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study. (Pubmed Central) - Apr 25, 2019
P4
The visual acuity gains and anatomic improvements observed at year one were maintained through month 24 with less visits and treatments. This may help minimize the treatment burden in patients with recurrent macular edema secondary to non-ischemic CRVO.Trial Registration ClinicalTrials.gov, NCT01870427, Registered June 6, 2013, https://clinicaltrials.gov/ct2/show/NCT01870427?cond=NEWTON&rank=1.Presented at the RETICON 2017: The Retina Congress with Live Surgery, Chennai, India-April 2017.
- |||||||||| Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: LADDER: Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Apr 25, 2019
P2, N=232, Completed,
This may help minimize the treatment burden in patients with recurrent macular edema secondary to non-ischemic CRVO.Trial Registration ClinicalTrials.gov, NCT01870427, Registered June 6, 2013, https://clinicaltrials.gov/ct2/show/NCT01870427?cond=NEWTON&rank=1.Presented at the RETICON 2017: The Retina Congress with Live Surgery, Chennai, India-April 2017. Active, not recruiting --> Completed
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor (Pubmed Central) - Apr 20, 2019
The efficacy of anti-vascular endothelial growth factor in the treatment of retinopathy of incontinentia pigmenti was prelininarily confimed.However,the optimal use timing,dosage,local and systemic safety issues were needed to be further studied. (Chin J Ophthalmol, 2019, 55:294-301).
- |||||||||| NN1213 / Novo Nordisk, Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: Noctura400 Treatment for Diabetic Retinopathy (CANDLE) (clinicaltrials.gov) - Apr 19, 2019
P=N/A, N=252, Active, not recruiting,
(Chin J Ophthalmol, 2019, 55:294-301). Trial completion date: Jun 2018 --> Jan 2020 | Trial primary completion date: Jun 2018 --> Jan 2020
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. (Pubmed Central) - Apr 18, 2019
Available information on the adverse effects of each medication does not suggest a higher incidence of potentially vision-threatening complications with intravitreous injection of anti-VEGF agents compared with control interventions; however, clinical trial sample sizes were not sufficient to estimate differences in rare safety outcomes. Future Cochrane Reviews should incorporate research evaluating variable dosing regimens of anti-VEGF agents, effects of long-term use, use of combination therapies (e.g. anti-VEGF treatment plus photodynamic therapy), and other methods of delivering these agents.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal: One-step solid-oil-water emulsion for sustained bioactive ranibizumab release. (Pubmed Central) - Apr 17, 2019
HbA1c is not related to functional or anatomical outcomes at 1 year in DME treated with ranibizumab. The use of SOW encapsulation in modulating ranibizumab release while maintaining their bioactivity has been highlighted.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Evaluation of intravitreal injection practice patterns in Cotonou (Pubmed Central) - Apr 14, 2019
The indications are many, and ocular hypertension is a significant complication. The difficulties in terms of supply and preservation of the main drugs used (anti-VEGF) remains to be resolved.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. (Pubmed Central) - Apr 11, 2019
Thus, OCT-A could be more useful in the diagnosis than in the follow-up of mCNV. Ranibizumab 0.5Â mg PRN demonstrated a statistically significant and clinically meaningful treatment effect versus laser and was well tolerated in Chinese patients with visual impairment due to DME over 12Â months.
- |||||||||| Rimmyrah (ranibizumab biosimilar) / Biocad, Qilu Pharma
Trial completion, Trial completion date, Trial primary completion date: Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis (clinicaltrials.gov) - Apr 11, 2019
P1, N=48, Completed,
"Treat and monitor" regimen is a real-life effective strategy in improving visual acuity after macular edema from branch vein occlusion and in reducing the number of injections. Recruiting --> Completed | Trial completion date: Oct 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Apr 2019
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal: Diabetic retinopathy and age-related macular degeneration: a survey of pharmacoutilization and cost in Calabria, Italy. (Pubmed Central) - Apr 10, 2019
Therefore, appropriateness of treatment with drugs other than ranibizumab needs to be assessed in this setting and deep monitoring of pharmacologic treatment for retinal diseases is necessary to prevent or delay visual acuity decrease and complete vision loss. Study procedures were performed in accordance with the "Mater Domini" University Hospital ethical standards of the responsible committee on human experimentation.
- |||||||||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. (Pubmed Central) - Apr 10, 2019
Bevacizumab, ranibizumab, and aflibercept injections are effective treatments for nAMD and have similar responses, although the number of injections of aflibercept was fewer than other anti-VEGF agents. In addition, aflibercept injections may be a better choice than other anti-VEGF agents for cases of severe increases in PED height.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Two-Year Follow-up Results of Patients with Macular Oedema Due to Retinal Vein Occlusion Treated with Ranibizumab (Pubmed Central) - Apr 10, 2019
According to our results intravitreal ranibizumab is a safe and effective treatment for ME caused by retinal vein occlusion. Our results in BRVO group were in accordance with published international studies - BRAVO (BRVO) +18,3 letters, HORIZON -0,7 and even slightly better in CRVO group - CRUISE (CRVO) +13,9 letters, HORIZON study -4,1 lettersKey words: macular oedema, ranibizumab, retinal vein occlusion, central retinal vein occlusion, branch retinal vein occlusion, 2-year follow-up.
- |||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration. (Pubmed Central) - Apr 10, 2019
Our results in BRVO group were in accordance with published international studies - BRAVO (BRVO) +18,3 letters, HORIZON -0,7 and even slightly better in CRVO group - CRUISE (CRVO) +13,9 letters, HORIZON study -4,1 lettersKey words: macular oedema, ranibizumab, retinal vein occlusion, central retinal vein occlusion, branch retinal vein occlusion, 2-year follow-up. Although aflibercept was found to be superior to ranibizumab regarding BCVA improvement, both agents showed anatomical effectiveness with significant reduction in PED height and SRF absorption in patients with vPED due to AMD.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study). (Pubmed Central) - Apr 5, 2019
Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Nov 2019 | Trial primary completion date: Feb 2019 --> Nov 2019 Switching from bevacizumab to ranibizumab in persistent diabetic macular edema was associated with anatomical improvement in the majority of eyes and ⩾2 lines of vision improvement in 22% of eyes.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal: Optical coherence tomography angiography in myopic choroidal neovascularization after intravitreal ranibizumab. (Pubmed Central) - Apr 5, 2019
Switching from bevacizumab to ranibizumab in persistent diabetic macular edema was associated with anatomical improvement in the majority of eyes and ⩾2 lines of vision improvement in 22% of eyes. Our data suggest that optical coherence tomography angiography is a reproducible non-invasive examination with which to monitor changes in the neovascular area in patients with pathologic myopia treated with ranibizumab.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Combination therapy: A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME) (clinicaltrials.gov) - Apr 5, 2019
P2, N=70, Active, not recruiting,
Our data suggest that optical coherence tomography angiography is a reproducible non-invasive examination with which to monitor changes in the neovascular area in patients with pathologic myopia treated with ranibizumab. Recruiting --> Active, not recruiting
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal: QbD Based Media Development for the Production of Fab Fragments in E. coli. (Pubmed Central) - Mar 31, 2019
Ranibizumab is a biotherapeutic Fab fragment used for the treatment of age-related macular degeneration and macular oedema...Product identification was performed with Liquid Chromatographyâ»Mass Spectrometry (LC-MS), the expression level was quantified using Bio-layer Interferometry, Reverse Phase-HPLC, and SDS-PAGE, and product quality were measured by RP-HPLC. Overall, a five-fold enhancement of the target protein titer was obtained (from 5 mg/L to 25 mg/L) using the screened medium components vis-a-vis the basal medium, thereby demonstrating the efficacy of the systematic approach purported by QbD.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Real-life Data on the Treatment of Diabetic Macular Oedema in Germany (Pubmed Central) - Mar 29, 2019
...Here we report a case series from our clinical routine of patients treated with ranibizumab for visual significant DME...This can partially be explained by differences in study populations and a negative selection bias in longer term results. However, additional barriers that hamper timely treatment tailored to disease activity requirements must be identified and circumvented where possible.
- |||||||||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: Asia-Pacific Technology and Trend Survey 2016-2017. (Pubmed Central) - Mar 27, 2019
Additional studies with long-term follow-up are needed to support our conclusion. The survey revealed information that may be close to real-world practices in the Asia-Pacific region and could be of help to understand the transformation of global trends and practices due to evolving evidence and technologies.
- |||||||||| Ozurdex (dexamethasone intravitreal implant) / Allergan, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal, HEOR: Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema. (Pubmed Central) - Mar 27, 2019
The survey revealed information that may be close to real-world practices in the Asia-Pacific region and could be of help to understand the transformation of global trends and practices due to evolving evidence and technologies. The inclusion of an intravitreal dexamethasone implant for the treatment of diabetic macular oedema would lead to cost-savings for the considered health area, mainly by reducing the administration costs.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye. (Pubmed Central) - Mar 24, 2019
No significant difference was noted in CRAE in the non-treated eyes of the ranibizumab group at any post-injection visit (PÂ =Â 0.1). A significant transient narrowing effect of bevacizumab on retinal arterioles in the fellow non-treated eyes on the third day after intravitreal injection may show that plasma concentrations of these drugs are sufficient to spread the effect to the other eye.
|
